Drug-drug-gene interactions as mediators of adverse drug reactions to diclofenac and statins: a case report and literature review

1Routledge PA, O’Mahony MS, Woodhouse KW. Adverse drug reactions in elderly patients. Br J Clin Pharmacol 2004;57:121–6. doi: 10.1046/j.1365-2125.2003.01875.x Routledge PA O’Mahony MS, Woodhouse KW Adverse drug reactions in elderly patients Br J Clin Pharmacol 2004 57121 6 10.1046/j.1365-2125.2003.01875.x188442814748810Open DOISearch in Google Scholar

2Alhawassi TM, Krass I, Bajorek BV, Pont LG. A systematic review of the prevalence and risk factors for adverse drug reactions in the elderly in the acute care setting. Clin Interv Aging 2014;9:2079–86. doi: 10.2147/CIA.S71178 Alhawassi TM Krass I Bajorek BV Pont LG A systematic review of the prevalence and risk factors for adverse drug reactions in the elderly in the acute care setting Clin Interv Aging 2014 92079 86 10.2147/CIA.S71178425702425489239Open DOISearch in Google Scholar

3US Food and Drug Administration. Preventable Adverse Drug Reactions: A Focus on Drug Interactions 2018 [displayed 30 December 2020]. Available at https://www.fda.gov/drugs/drug-interactions-labeling/preventable-adverse-drug-reactions-focus-drug-interactions US Food and Drug Administration Preventable Adverse Drug Reactions: A Focus on Drug Interactions 2018 [displayed 30 December 2020]. Available at https://www.fda.gov/drugs/drug-interactions-labeling/preventable-adverse-drug-reactions-focus-drug-interactionsSearch in Google Scholar

4Malki MA, Pearson ER. Drug-drug-gene interactions and adverse drug reactions. Pharmacogenomics J 2020;20:355–66. doi: 10.1038/s41397-019-0122-0 Malki MA Pearson ER Drug-drug-gene interactions and adverse drug reactions Pharmacogenomics J 2020 20355–66 10.1038/s41397-019-0122-0725335431792369Open DOISearch in Google Scholar

5Verbeurgt P, Mamiya T, Oesterheld J. How common are drug and gene interactions? Prevalence in a sample of 1143 patients with CYP2C9, CYP2C19 and CYP2D6 genotyping. Pharmacogenomics 2014;15:655–65. doi: 10.2217/pgs.14.6 Verbeurgt P Mamiya T Oesterheld J How common are drug and gene interactions? Prevalence in a sample of 1143 patients with CYP2C9, CYP2C19 and CYP2D6 genotyping Pharmacogenomics 2014 15655 65 10.2217/pgs.14.624798722Open DOISearch in Google Scholar

6Bahar MA, Setiawan D, Hak E, Wilffert B. Pharmacogenetics of drug-drug interaction and drug-drug-gene interaction: a systematic review on CYP2C9, CYP2C19 and CYP2D6. Pharmacogenomics 2017;18:701–39. doi: 10.2217/pgs-2017-0194 Bahar MA Setiawan D Hak E Wilffert B Pharmacogenetics of drug-drug interaction and drug-drug-gene interaction: a systematic review on CYP2C9, CYP2C19 and CYP2D6 Pharmacogenomics 2017 18701 39 10.2217/pgs-2017-019428480783Open DOISearch in Google Scholar

7Wojtyniak JG, Selzer D, Schwab M, Lehr T. Physiologically based precision dosing approach for drug-drug-gene interactions: a simvastatin network analysis. Clin Pharmacol Ther 2021;109:201–11. doi: 10.1002/cpt.2111 Wojtyniak JG Selzer D Schwab M Lehr T Physiologically based precision dosing approach for drug-drug-gene interactions: a simvastatin network analysis Clin Pharmacol Ther 2021 109201 11 10.1002/cpt.211133280091Open DOISearch in Google Scholar

8Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 2013;138:103–41. doi: 10.1016/j.pharmthera.2012.12.007 Zanger UM Schwab M Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation Pharmacol Ther 2013 138103 41 10.1016/j.pharmthera.2012.12.00723333322Open DOISearch in Google Scholar

9Guengerich FP. Intersection of the roles of cytochrome P450 enzymes with xenobiotic and endogenous substrates: relevance to toxicity and drug interactions. Chem Res Toxicol 2017;30:2–12. doi: 10.1021/acs.chemrestox.6b00226 Guengerich FP Intersection of the roles of cytochrome P450 enzymes with xenobiotic and endogenous substrates: relevance to toxicity and drug interactions Chem Res Toxicol 2017 302 12 10.1021/acs.chemrestox.6b00226529373027472660Open DOISearch in Google Scholar

10Sim SC, Kacevska M, Ingelman-Sundberg M. Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects. Pharmacogenomics J 2013;13:1–11. doi: 10.1038/tpj.2012.45 Sim SC Kacevska M Ingelman-Sundberg M Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects Pharmacogenomics J 2013 131 11 10.1038/tpj.2012.4523089672Open DOISearch in Google Scholar

11Swen JJ, Nijenhuis M, van Rhenen M, de Boer-Veger NJ, Buunk AM, Houwink EJF, Mulder H, Rongen GA, van Schaik RHN, van der Weide J, Wilffert B, Deneer VHM, Guchelaar H-J, on behalf of the DutchPharmacogenetics Working Group (DPWG) of the Royal Dutch Pharmacists Association (KNMP). Pharmacogenetic information in clinical guidelines: The European perspective. Clin Pharmacol Ther 2018;103:795–801. doi: 10.1002/cpt.1049 Swen JJ Nijenhuis M van Rhenen M de Boer-Veger NJ Buunk AM Houwink EJF Mulder H Rongen GA van Schaik RHN van der Weide J Wilffert B Deneer VHM Guchelaar H-J on behalf of the DutchPharmacogenetics Working Group (DPWG) of the Royal Dutch Pharmacists Association (KNMP) Pharmacogenetic information in clinical guidelines: The European perspective Clin Pharmacol Ther 2018 103795 801 10.1002/cpt.104929460273Open DOISearch in Google Scholar

12Youssef, E, Kirkdale, CL, Wright, DJ, Guchelaar, H-J, Thornley, T. Estimating the potential impact of implementing pre-emptive pharmacogenetic testing in primary care across the UK. Br J Clin Pharmacol 2021;1–19. doi: 10.1111/bcp.14704 Youssef E Kirkdale CL Wright DJ Guchelaar H-J Thornley T Estimating the potential impact of implementing pre-emptive pharmacogenetic testing in primary care across the UK. Br J Clin Pharmacol 2021 1–19 10.1111/bcp.1470433464647Open DOISearch in Google Scholar

13Arjomand-Nahad F, Diefenbach K, Landt O, Gaikovitch E, Roots I. Genotyping of the triallelic variant G2677T/A in MDR1 using LightCycler with locked-nucleic-acid-modified hybridization probes. Anal Biochem 2004;334:201–3. doi: 10.1016/j.ab.2004.07.030 Arjomand-Nahad F Diefenbach K Landt O Gaikovitch E Roots I Genotyping of the triallelic variant G2677T/A in MDR1 using LightCycler with locked-nucleic-acid-modified hybridization probes Anal Biochem 2004 334201 3 10.1016/j.ab.2004.07.03015464971Open DOISearch in Google Scholar

14Steijns LSW, Van Der Weide J. Ultrarapid drug metabolism: PCR-based detection of CYP2D6 gene duplication. Clin Chem 1998;44:914–7. doi: 10.1093/clinchem/44.5.914 Steijns LSW Van Der Weide J Ultrarapid drug metabolism: PCR-based detection of CYP2D6 gene duplication Clin Chem 1998 44914 7 10.1093/clinchem/44.5.914Open DOISearch in Google Scholar

15Stuven T, Griese EU, Kroemer HK, Eichelbaum M, Zanger UM. Rapid detection of CYP2D6 null alleles by long distance- and multiplex-polymerase chain reaction. Pharmacogenetics 1996;6:417–21. doi: 10.1097/00008571199610000-00005 Stuven T Griese EU Kroemer HK Eichelbaum M Zanger UM Rapid detection of CYP2D6 null alleles by long distance- and multiplex-polymerase chain reaction Pharmacogenetics 1996 6417 21 10.1097/00008571199610000-00005Open DOISearch in Google Scholar

16Clinical Pharmacogenetics Implementation Consortium (CPIC) [displayed 15 March 2021]. Available at https://cpicpgx.org/guidelines/ Clinical Pharmacogenetics Implementation Consortium (CPIC) [displayed 15 March 2021] Available at https://cpicpgx.org/guidelines/Search in Google Scholar

17The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG). DPWG Pharmacogenomics guidelines [displayed 30 December 2020]. Available at https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2020.pdf The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) DPWG Pharmacogenomics guidelines [displayed 30 December 2020 Available at https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2020.pdfSearch in Google Scholar

18Agency for Medicinal Products and Medical Devices of Croatia (HALMED). Croatian Annual Report on Drug Utilisation for 2019 [displayed 30 15 March 2021]. Available at https://www.halmed.hr/Novosti-i-edukacije/Publikacije-i-izvjesca/Izvjesca-o-potrosnji-lijekova Agency for Medicinal Products and Medical Devices of Croatia (HALMED) Croatian Annual Report on Drug Utilisation for 2019 [displayed 30 15 March 2021]. Available at https://www.halmed.hr/Novosti-i-edukacije/Publikacije-i-izvjesca/Izvjesca-o-potrosnji-lijekovaSearch in Google Scholar

19Davies NM, Anderson KE. Clinical pharmacokinetics of diclofenac. Therapeutic insights and pitfalls. Clin Pharmacokinet 1997;33:184–213. doi: 10.2165/00003088199733030-00003 Davies NM Anderson KE Clinical pharmacokinetics of diclofenac Therapeutic insights and pitfalls. Clin Pharmacokinet 1997 33184 213 10.2165/00003088199733030-00003Open DOISearch in Google Scholar

20Tang W. The metabolism of diclofenac - enzymology and toxicology perspectives. Curr Drug Metab 2003;4:319–29. doi: 10.2174/1389200033489398 Tang W The metabolism of diclofenac - enzymology and toxicology perspectives Curr Drug Metab 2003 4319 29 10.2174/138920003348939812871048Open DOISearch in Google Scholar

21King C, Tang W, Ngui J, Tephly T, Braun M. Characterization of rat and human UDP-glucuronosyltransferases responsible for the in vitro glucuronidation of diclofenac. Toxicol Sci 2001;61:49–53. doi: 10.1093/toxsci/61.1.49 King C Tang W Ngui J Tephly T Braun M Characterization of rat and human UDP-glucuronosyltransferases responsible for the in vitro glucuronidation of diclofenac Toxicol Sci 2001 6149 53 10.1093/toxsci/61.1.4911294973Open DOISearch in Google Scholar

22Riess W, Stierlin H, Degen P, Faigle JW, Gerardin A, Moppert J, Sallmann A, Schmid K, Schweizer A, Sulc M, Theobald W, Wagner J. Pharmacokinetics and metabolism of the anti-inflammatory agent Voltaren. Scand J Rheumatol 1978;7(Suppl 22):17–29. doi: 10.3109/03009747809097212 Riess W Stierlin H Degen P Faigle JW Gerardin A Moppert J Sallmann A Schmid K Schweizer A Sulc M Theobald W Wagner J Pharmacokinetics and metabolism of the anti-inflammatory agent Voltaren Scand J Rheumatol 1978 7 Suppl 22 17 29 10.3109/0300974780909721298834Open DOISearch in Google Scholar

23Lagas JS, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. Hepatic clearance of reactive glucuronide metabolites of diclofenac in the mouse is dependent on multiple ATP-binding cassette efflux transporters. Mol Pharmacol 2010;77:687–94. doi: 10.1124/mol.109.062364 Lagas JS Sparidans RW Wagenaar E Beijnen JH Schinkel AH Hepatic clearance of reactive glucuronide metabolites of diclofenac in the mouse is dependent on multiple ATP-binding cassette efflux transporters Mol Pharmacol 2010 77687 94 10.1124/mol.109.06236420086033Open DOISearch in Google Scholar

24Scialis RJ, Aleksunes LM, Csanaky IL, Klaassen CD, Manautou JE. Identification and characterization of efflux transporters that modulate the subtoxic disposition of diclofenac and its metabolites. Drug Metab Dispos 2019;47:1080–92. doi: 10.1124/dmd.119.086603 Scialis RJ Aleksunes LM Csanaky IL Klaassen CD Manautou JE Identification and characterization of efflux transporters that modulate the subtoxic disposition of diclofenac and its metabolites Drug Metab Dispos 2019 471080 92 10.1124/dmd.119.086603675019031399506Open DOISearch in Google Scholar

25Zhang Y, Han YH, Putluru SP, Matta MK, Kole P, Mandlekar S, Furlong MT, Liu T, Iyer RA, Marathe P, Yang Z, Lai Y, Rodrigues AD. Diclofenac and its acyl glucuronide: determination of in vivo exposure in human subjects and characterization as human drug transporter substrates in vitro. Drug Metab Dispos 2016;44:320–8. doi: 10.1124/ dmd.115.066944 Zhang Y Han YH Putluru SP Matta MK Kole P Mandlekar S Furlong MT Liu T Iyer RA Marathe P Yang Z Lai Y Rodrigues AD Diclofenac and its acyl glucuronide: determination of in vivo exposure in human subjects and characterization as human drug transporter substrates in vitro Drug Metab Dispos 2016 44320 8 10.1124/dmd.115.06694426714763Open DOISearch in Google Scholar

26Tomlinson B, Chan P, Zhang Y, Liu Z, Lam CWK. Pharmacokinetics of current and emerging treatments for hypercholesterolemia. Expert Opin Drug Metab Toxicol 2020;16:371–85. doi: 10.1080/17425255.2020.1749261 Tomlinson B Chan P Zhang Y Liu Z Lam CWK Pharmacokinetics of current and emerging treatments for hypercholesterolemia Expert Opin Drug Metab Toxicol 2020 16371 85 10.1080/17425255.2020.174926132223657Open DOISearch in Google Scholar

27Iwuchukwu OF, Feng Q, Wei WQ, Jiang L, Jiang M, Xu H, Denny JC, Wilke RA, Krauss RM, Roden DM, Stein CM. Genetic variation in the UGT1A locus is associated with simvastatin efficacy in a clinical practice setting. Pharmacogenomics 2014;15:1739–47. doi: 10.2217/pgs.14.128 Iwuchukwu OF Feng Q Wei WQ Jiang L Jiang M Xu H Denny JC Wilke RA Krauss RM Roden DM Stein CM Genetic variation in the UGT1A locus is associated with simvastatin efficacy in a clinical practice setting Pharmacogenomics 2014 151739 47 10.2217/pgs.14.128429289425493567Open DOISearch in Google Scholar

28Hirota T, Fujita Y, Ieiri I. An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins. Expert Opin Drug Metab Toxicol 2020;16:809–22. doi: 10.1080/17425255.2020.1801634 Hirota T Fujita Y Ieiri I An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins Expert Opin Drug Metab Toxicol 2020 16809 22 10.1080/17425255.2020.180163432729746Open DOISearch in Google Scholar

29Turner RM, Pirmohamed M. Statin-related myotoxicity: a comprehensive review of pharmacokinetic, pharmacogenomic and muscle components. J Clin Med 2019;9(1):22. doi: 10.3390/jcm9010022 Turner RM Pirmohamed M Statin-related myotoxicity: a comprehensive review of pharmacokinetic, pharmacogenomic and muscle components J Clin Med 2019 9 1 22 10.3390/jcm9010022701983931861911Open DOISearch in Google Scholar

30Park JE, Kim KB, Bae SK, Moon BS, Liu KH, Shin JG. Contribution of cytochrome P450 3A4 and 3A5 to the metabolism of atorvastatin. Xenobiotica 2008;38:1240–51. doi: 10.1080/00498250802334391 Park JE Kim KB Bae SK Moon BS Liu KH Shin JG Contribution of cytochrome P450 3A4 and 3A5 to the metabolism of atorvastatin Xenobiotica 2008 381240 51 10.1080/0049825080233439118720283Open DOISearch in Google Scholar

31Yasar U, Sain-Guven G, Yardimci Y, Kilicarslan A, Babaoglu MO, Bozkurt A. Effect of atorvastatin on CYP2C9 metabolic activity as measured by the formation rate of losartan metabolite in hypercholesterolaemic patients. Basic Clin Pharmacol Toxicol 2 0 1 1 ; 1 0 9 : 7 3 – 7 . doi: 10.1111/j.1742-7843.2011.00687.x Yasar U Sain-Guven G Yardimci Y Kilicarslan A Babaoglu MO Bozkurt A Effect of atorvastatin on CYP2C9 metabolic activity as measured by the formation rate of losartan metabolite in hypercholesterolaemic patients Basic Clin Pharmacol Toxicol 2 0 1 1 ; 1 0 9 : 7 3 – 7 10.1111/j.1742-7843.2011.00687.x21332946Open DOISearch in Google Scholar

32Vickers S, Duncan CA, Vyas KP, Kari PH, Arison B, Prakash SR, Ramjit HG, Pitzenberger SM, Stokker G, Duggan DE. In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase. Drug Metab Dispos 1990;18:476–83. PMID: 1976071 Vickers S Duncan CA Vyas KP Kari PH Arison B Prakash SR Ramjit HG Pitzenberger SM Stokker G Duggan DE In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase Drug Metab Dispos 1990 18476 83 PMID: 1976071Search in Google Scholar

33Lennernäs H. Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet 2003;42:1141–60. doi: 10.2165/00003088200342130-00005 Lennernäs H Clinical pharmacokinetics of atorvastatin Clin Pharmacokinet 2003 421141 60 10.2165/00003088200342130-00005Open DOISearch in Google Scholar

34Goosen TC, Bauman JN, Davis JA, Yu C, Hurst SI, Williams JA, Loi C-M. Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid. Drug Metab Dispos 2007;35:1315–24. doi: 10.1124/dmd.107.015230 Goosen TC Bauman JN Davis JA Yu C Hurst SI Williams JA Loi C-M Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid Drug Metab Dispos 2007 351315 24 10.1124/dmd.107.01523017470524Open DOISearch in Google Scholar

35Riedmaier S, Klein K, Hofmann U, Keskitalo JE, Neuvonen PJ, Schwab M, Niemi M, Zanger UM. UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo. Clin Pharmacol Ther 2010;87:65–73. doi: 10.1038/clpt.2009.181 Riedmaier S Klein K Hofmann U Keskitalo JE Neuvonen PJ Schwab M Niemi M Zanger UM UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo Clin Pharmacol Ther 2010 8765 73 10.1038/clpt.2009.18119794410Open DOISearch in Google Scholar

36Prueksaritanont T, Subramanian R, Fang X, Ma B, Qiu Y, Lin JH, Pearson PG, Baillie TA. Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab Dispos 2002;30:505–12. doi: 10.1124/dmd.30.5.505 Prueksaritanont T Subramanian R Fang X Ma B Qiu Y Lin JH Pearson PG Baillie TA Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization Drug Metab Dispos 2002 30505 12 10.1124/dmd.30.5.50511950779Open DOISearch in Google Scholar

37Wei WQ, Feng Q, Jiang L, Waitara MS, Iwuchukwu OF, Roden DM, Jiang M, Xu H, Krauss RM; Rotter JI, Nickerson DA, Davis RL, Berg RL, Peissig PL, McCarty CA, Wilke RA, Denny JC. Characterization of statin dose response in electronic medical records. Clin Pharmacol Ther 2014;95:331–8. doi: 10.1038/clpt.2013.202 Wei WQ Feng Q Jiang L Waitara MS Iwuchukwu OF Roden DM Jiang M Xu H Krauss RM; Rotter JI Nickerson DA Davis RL Berg RL Peissig PL McCarty CA Wilke RA Denny JC Characterization of statin dose response in electronic medical records Clin Pharmacol Ther 2014 95331 8 10.1038/clpt.2013.202394421424096969Open DOISearch in Google Scholar

38Keskitalo JE, Kurkinen KJ, Neuvoneni PJ, Niemi M. ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin. Clin Pharmacol Ther 2008;84:457–61. doi: 10.1038/clpt.2008.25 Keskitalo JE Kurkinen KJ Neuvoneni PJ Niemi M ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin Clin Pharmacol Ther 2008 84457 61 10.1038/clpt.2008.2519238649Open DOISearch in Google Scholar

39Keskitalo JE, Zolk O, Fromm MF, Kurkinen KJ, Neuvonen PJ, Niemi M. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 2009;86:197–203. doi: 10.1038/clpt.2009.79 Keskitalo JE Zolk O Fromm MF Kurkinen KJ Neuvonen PJ Niemi M ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin Clin Pharmacol Ther 2009 86197 203 10.1038/clpt.2009.7919474787Open DOISearch in Google Scholar

40Niemi M. Transporter pharmacogenetics and statin toxicity. Clin Pharmacol Ther 2010;87:130–3. doi: 10.1038/ clpt.2009.197 Niemi M Transporter pharmacogenetics and statin toxicity Clin Pharmacol Ther 2010 87130 3 10.1038/clpt.2009.19719890253Open DOISearch in Google Scholar

41Nies AT, Niemi M, Burk O, Winter S, Zanger UM, Stieger B, Schwab M, Schaeffeler E. Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1. Genome Med 2013;5(1):1. doi: 10.1186/gm405 Nies AT Niemi M Burk O Winter S Zanger UM Stieger B Schwab M Schaeffeler E Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1 Genome Med 2013 5 1 1 10.1186/gm405370689023311897Open DOISearch in Google Scholar

42Moßhammer D, Schaeffeler E, Schwab M, Mörike K. Mechanisms and assessment of statin-related muscular adverse effects. Br J Clin Pharmacol 2014;78:454–66. doi: 10.1111/bcp.12360 Moßhammer D Schaeffeler E Schwab M Mörike K Mechanisms and assessment of statin-related muscular adverse effects Br J Clin Pharmacol 2014 78454 66 10.1111/bcp.12360424389725069381Open DOISearch in Google Scholar

43Cascorbi I, Haenisch S. Pharmacogenetics of ATP-binding cassette transporters and clinical implications. Methods Mol Biol 2010;596:95–121. doi: 10.1007/978-1-60761-416-6_6 Cascorbi I Haenisch S Pharmacogenetics of ATP-binding cassette transporters and clinical implications Methods Mol Biol 2010 59695 121 10.1007/978-1-60761-416-6_619949922Open DOISearch in Google Scholar

44Nie Y, Yang J, Liu S, Sun R, Chen H, Long N, Jiang R, Gui C. Genetic polymorphisms of human hepatic OATPs: functional consequences and effect on drug pharmacokinetics. Xenobiotica 2020; 50: 297 – 317 . doi: 10.1080/00498254.2019.1629043 Nie Y Yang J Liu S Sun R Chen H Long N Jiang R Gui C Genetic polymorphisms of human hepatic OATPs: functional consequences and effect on drug pharmacokinetics Xenobiotica 2020; 50: 297 – 317 10.1080/00498254.2019.162904331180267Open DOISearch in Google Scholar

45Menassé R, Hedwall PR, Kraetz J, Pericin C, Riesterer L, Sallmann A, Ziel R, Jaques R. Pharmacological properties of diclofenac sodium and its metabolites. Scand J Rheumatol 1978;7(Suppl 22):5–16. doi: 10.3109/03009747809097211 Menassé R Hedwall PR Kraetz J Pericin C Riesterer L Sallmann A Ziel R Jaques R Pharmacological properties of diclofenac sodium and its metabolites Scand J Rheumatol 1978 7 Suppl 22 5 16 10.3109/0300974780909721198835Open DOISearch in Google Scholar

46Kim G-H. Renal effects of prostaglandins and cyclooxygenase-2 inhibitors. Electrolyte Blood Press 2008;6:35–41. doi: 10.5049/EBP.2008.6.1.35 Kim G-H Renal effects of prostaglandins and cyclooxygenase-2 inhibitors Electrolyte Blood Press 2008 635 41 10.5049/EBP.2008.6.1.35Open DOISearch in Google Scholar

47Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med 1999;106(5B):13S-24S. doi: 10.1016/s0002-9343(99)00113-8 Whelton A Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications Am J Med 1999 106 5B 13S 24 S 10.1016/s0002-9343(99)00113-8Open DOISearch in Google Scholar

48John CM, Shukla R, Jones CA. Using NSAID in volume depleted children can precipitate acute renal failure. Arch Dis Child 2007;92:524–6. doi: 10.1136/adc.2006.103564 John CM Shukla R Jones CA Using NSAID in volume depleted children can precipitate acute renal failure Arch Dis Child 2007 92524 6 10.1136/adc.2006.103564206613017293366Open DOISearch in Google Scholar

49Zi J, Liu D, Ma P, Huang H, Zhu J, Wei D, Yang J, Chen C. Effects of CYP2C9*3 and CYP2C9*13 on diclofenac metabolism and inhibition-based drug-drug interactions. Drug Metab Pharmacokinet 2010;25:343–50. doi: 10.2133/ dmpk.dmpk-10-rg-009 Zi J Liu D Ma P Huang H Zhu J Wei D Yang J Chen C Effects of CYP2C9*3 and CYP2C9*13 on diclofenac metabolism and inhibition-based drug-drug interactions Drug Metab Pharmacokinet 2010 25343 50 10.2133/dmpk.dmpk-10-rg-00920814155Open DOISearch in Google Scholar

50Maekawa K, Harakawa N, Sugiyama E, Tohkin M, Kim SR, Kaniwa N, Katori N, Hasegawa R, Yasuda K, Kamide K, Miyata T, Saito Y, Sawada J. Substrate-dependent functional alterations of seven CYP2C9 variants found in Japanese subjects. Drug Metab Dispos 2009;37:1895–903. doi: 10.1124/dmd.109.027003 Maekawa K Harakawa N Sugiyama E Tohkin M Kim SR Kaniwa N Katori N Hasegawa R Yasuda K Kamide K Miyata T Saito Y Sawada J Substrate-dependent functional alterations of seven CYP2C9 variants found in Japanese subjects Drug Metab Dispos 2009 371895 903 10.1124/dmd.109.02700319541829Open DOISearch in Google Scholar

51Xia M-M, Wang L, PAan P-P, Wang H-Y, Chen M-C, Chen Y, Dai D-P, Cai J-P, Hu G-X. The role of CYP2C9 genetic polymorphisms in the oxidative metabolism of diclofenac in vitro. Pharmazie 2014;69:898–903. PMID: 25951663 Xia M-M Wang L PAan P-P, Wang H-Y Chen M-C Chen Y Dai D-P Cai J-P Hu G-X The role of CYP2C9 genetic polymorphisms in the oxidative metabolism of diclofenac in vitro Pharmazie 2014 69898 903 PMID: 25951663Search in Google Scholar

52Dorado P, Cavaco I, Cáceres MC, Piedade R, Ribeiro V, Llerena A. Relationship between CYP2C8 genotypes and diclofenac 5-hydroxylation in healthy Spanish volunteers. Eur J Clin Pharmacol 2008;64:967–70. doi: 10.1007/s00228-008-0508-4 Dorado P Cavaco I Cáceres MC, Piedade R Ribeiro V Llerena A Relationship between CYP2C8 genotypes and diclofenac 5-hydroxylation in healthy Spanish volunteers Eur J Clin Pharmacol 2008 64967 70 10.1007/s00228-008-0508-418548238Open DOISearch in Google Scholar

53Kirchheiner J, Meineke I, Steinbach N, Meisel C, Roots I, Brockmöller J. Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans. Br J Clin Pharmacol 2003;55:51–61. doi: 10.1046/j.1365-2125.2003.01712.x Kirchheiner J Meineke I Steinbach N Meisel C Roots I Brockmöller J Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans Br J Clin Pharmacol 2003 5551 61 10.1046/j.1365-2125.2003.01712.x188419212534640Open DOISearch in Google Scholar

54Theken KN, Lee CR, Gong L, Caudle KE, Formea CM, Gaedigk A, Klein TE, Agúndez JAG, Grosser T. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and nonsteroidal anti-inflammatory drugs. Clin Pharmacol Ther 2020;108:191–200. doi: 10.1002/ cpt.1830 Theken KN Lee CR Gong L Caudle KE Formea CM Gaedigk A Klein TE Agúndez JAG Grosser T Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and nonsteroidal anti-inflammatory drugs Clin Pharmacol Ther 2020 108191 200 10.1002/cpt.1830808088232189324Open DOISearch in Google Scholar

55Shahabi P, Siest G, Meyer UA, Visvikis-Siest S. Human cytochrome P450 epoxygenases: variability in expression and role in inflammation-related disorders. Pharmacol Ther 2014;144:134–61. doi: 10.1016/j.pharmthera.2014.05.011 Shahabi P Siest G Meyer UA Visvikis-Siest S Human cytochrome P450 epoxygenases: variability in expression and role in inflammation-related disorders Pharmacol Ther 2014 144134 61 10.1016/j.pharmthera.2014.05.01124882266Open DOISearch in Google Scholar

56Capdevila JH, Wang W, Falck JR. Arachidonic acid monooxygenase: Genetic and biochemical approaches to physiological/pathophysiological relevance. Prostaglandins Other Lipid Mediat 2015;120:40–9. doi: 10.1016/j. prostaglandins.2015.05.004 Capdevila JH Wang W Falck JR Arachidonic acid monooxygenase: Genetic and biochemical approaches to physiological/pathophysiological relevance Prostaglandins Other Lipid Mediat 2015 12040 9 10.1016/j.prostaglandins.2015.05.004457560925986599Open DOISearch in Google Scholar

57Fan F, Roman RJ. Effect of cytochrome P450 metabolites of arachidonic acid in nephrology. J Am Soc Nephrol 2017;28:2845–55. doi: 10.1681/ASN.2017030252 Fan F Roman RJ Effect of cytochrome P450 metabolites of arachidonic acid in nephrology J Am Soc Nephrol 2017 282845 55 10.1681/ASN.2017030252561997628701518Open DOISearch in Google Scholar

58Fan F, Ge Y, Lv W, Elliott MR, Muroya Y, Hirata T, Booz GW, Roman RJ. Molecular mechanisms and cell signaling of 20-hydroxyeicosatetraenoic acid in vascular pathophysiology. Front Biosci (Landmark Ed) 2016;21:1427–63. PMCID: PMC5064940 Fan F Ge Y Lv W Elliott MR Muroya Y Hirata T Booz GW Roman RJ Molecular mechanisms and cell signaling of 20-hydroxyeicosatetraenoic acid in vascular pathophysiology Front Biosci (Landmark Ed) 2016 211427–63 PMCID: PMC506494010.2741/4465506494027100515Search in Google Scholar

59Dey A, Maric C, Kaesemeyer WH, Zaharis CZ, Stewart J, Pollock JS, Imig JD. Rofecoxib decreases renal injury in obese Zucker rats. Clin Sci (Lond) 2004;107:561–70. doi: 10.1042/CS20040125 Dey A Maric C Kaesemeyer WH Zaharis CZ Stewart J Pollock JS Imig JD Rofecoxib decreases renal injury in obese Zucker rats Clin Sci (Lond) 2004 107561 70 10.1042/CS2004012515307815Open DOISearch in Google Scholar

60Sausville LN, Gangadhariah MH, Chiusa M, Mei S, Wei S, Zent R, Luther JM, Shuey MM, Capdevila JH, Falck JR, Guengerich FP, Williams SM, Pozzi A. The cytochrome P450 slow metabolizers CYP2C9*2 and CYP2C9*3 directly regulate tumorigenesis via reduced epoxyeicosatrienoic acid production. Cancer Res 2018;78:4865–77. doi: 10.1158-0008-5472.CAN-17-3977 Sausville LN Gangadhariah MH Chiusa M Mei S Wei S Zent R Luther JM Shuey MM Capdevila JH Falck JR Guengerich FP Williams SM Pozzi A The cytochrome P450 slow metabolizers CYP2C9*2 and CYP2C9*3 directly regulate tumorigenesis via reduced epoxyeicosatrienoic acid production Cancer Res 2018 784865 77 10.1158-0008-5472.CAN-17-3977Open DOISearch in Google Scholar

61Imig JD. Epoxyeicosatrienoic acids, hypertension, and kidney injury. Hypertension 2015;65:476–82. doi: 10.1161/HYPERTENSIONAHA.114.03585 Imig JD Epoxyeicosatrienoic acids, hypertension, and kidney injury Hypertension 2015 65476 82 10.1161/HYPERTENSIONAHA.114.03585432658525583156Open DOISearch in Google Scholar

62Imig JD, Khan MAH. Cytochrome P450 and lipoxygenase metabolites on renal function. Compr Physiol 2015;6:423–41. doi: 10.1002/cphy.c150009 Imig JD Khan MAH Cytochrome P450 and lipoxygenase metabolites on renal function Compr Physiol 2015 6423 41 10.1002/cphy.c150009596526026756638Open DOISearch in Google Scholar

63Das A, Weigle AT, Arnold WR, Kim JS, Carnevale LN, Huff HC. CYP2J2 molecular recognition: a new axis for therapeutic design. Pharmacol Ther 2020;215:107601. doi: 10.1016/j.pharmthera.2020.107601 Das A Weigle AT Arnold WR Kim JS Carnevale LN Huff HC CYP2J2 molecular recognition: a new axis for therapeutic design Pharmacol Ther 2020 215107601 10.1016/j.pharmthera.2020.107601777314832534953Open DOISearch in Google Scholar

64Wang SY, Xing PF, Zhang CY, Deng BQ. Association of CYP2J2 gene polymorphisms with ischemic stroke and stroke subtypes in Chinese population. Medicine (Baltimore) 2017;96(10):e6266. doi: 10.1097/MD.0000000000006266 Wang SY Xing PF Zhang CY Deng BQ Association of CYP2J2 gene polymorphisms with ischemic stroke and stroke subtypes in Chinese population Medicine (Baltimore) 2017 96 10 e6266 10.1097/MD.0000000000006266534818428272236Open DOISearch in Google Scholar

65Jarrar YB, Cha E-Y, Seo K-A, Ghim J-L, Kim H-J, Kim D-H, Lee S-J, Shin J-G. Determination of major UDP-glucuronosyltransferase enzymes and their genotypes responsible for 20-HETE glucuronidation. J Lipid Res 2014;55:2334–42. doi: 10.1194/jlr.M051169 Jarrar YB Cha E-Y Seo K-A Ghim J-L Kim H-J Kim D-H Lee S-J Shin J-G Determination of major UDP-glucuronosyltransferase enzymes and their genotypes responsible for 20-HETE glucuronidation J Lipid Res 2014 552334 42 10.1194/jlr.M051169461713525249502Open DOISearch in Google Scholar

66Ward NC, Puddey IB, Hodgson JM, Beilin LJ, Croft KD. Urinary 20-hydroxyeicosatetraenoic acid excretion is associated with oxidative stress in hypertensive subjects. Free Radic Biol Med 2005;38:1032–6. doi: 10.1016/j.freeradbiomed.2004.12.024 Ward NC Puddey IB Hodgson JM Beilin LJ Croft KD Urinary 20-hydroxyeicosatetraenoic acid excretion is associated with oxidative stress in hypertensive subjects Free Radic Biol Med 2005 381032 6 10.1016/j.freeradbiomed.2004.12.02415780761Open DOISearch in Google Scholar

67Holthe M, Rakvåg TN, Klepstad P, Idle JR, Kaasa S, Krokan HE, Skorpen F. Sequence variations in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patients. Pharmacogenomics J 2003;3:17–26. doi: 10.1038/sj.tpj.6500139 Holthe M Rakvåg TN Klepstad P Idle JR Kaasa S Krokan HE Skorpen F Sequence variations in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patients Pharmacogenomics J 2003 317 26 10.1038/sj.tpj.650013912629580Open DOISearch in Google Scholar

68Daly AK, Aithal GP, Leathart JBS, Swainsbury RA, Dang TS, Day CP. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology 2007;132:272–81. doi: 10.1053/j.gastro.2006.11.023 Daly AK Aithal GP Leathart JBS Swainsbury RA Dang TS Day CP Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes Gastroenterology 2007 132272 81 10.1053/j.gastro.2006.11.02317241877Open DOISearch in Google Scholar

69Jarrar YB, Kim DH, Lee SJ, Shin JG. Inhibition of 20-hydroxyeicosatetraenoic acid (20-HETE) glucuronidation by non-steroidal anti-inflammatory drugs in human liver microsomes and recombinant UDP-glucuronosyltransferase enzymes. Prostaglandins Leukot Essent Fatty Acids 2020;153:102055. doi: 10.1016/j.plefa.2020.102055 Jarrar YB Kim DH Lee SJ Shin JG Inhibition of 20-hydroxyeicosatetraenoic acid (20-HETE) glucuronidation by non-steroidal anti-inflammatory drugs in human liver microsomes and recombinant UDP-glucuronosyltransferase enzymes Prostaglandins Leukot Essent Fatty Acids 2020 153102055 10.1016/j.plefa.2020.10205531999978Open DOISearch in Google Scholar

70Lazarska KE, Dekker SJ, Vermeulen NPE, Commandeur JNM. Effect of UGT2B7*2 and CYP2C8*4 polymorphisms on diclofenac metabolism. Toxicol Lett 2018;284:70–8. doi: 10.1016/j.toxlet.2017.11.038 Lazarska KE Dekker SJ Vermeulen NPE Commandeur JNM Effect of UGT2B7*2 and CYP2C8*4 polymorphisms on diclofenac metabolism Toxicol Lett 2018 28470 8 10.1016/j.toxlet.2017.11.03829203276Open DOISearch in Google Scholar

71Coffman BL, King CD, Rios GR, Tephly TR. The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). Drug Metab Dispos 1998;26:73–7. PMID: 9443856 Coffman BL King CD Rios GR Tephly TR The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268) Drug Metab Dispos 1998 2673 7 PMID: 9443856Search in Google Scholar

72Bélanger AS, Caron P, Harvey M, Zimmerman PA, Mehlotra RK, Guillemette C. Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine. Drug Metab Dispos 2009;37:1793–6. doi: 10.1124/dmd.109.027706 Bélanger AS Caron P Harvey M Zimmerman PA Mehlotra RK Guillemette C Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine Drug Metab Dispos 2009 371793 6 10.1124/dmd.109.027706272932519487252Open DOISearch in Google Scholar

73Barbier O, Turgeon D, Girard C, Green MD, Tephly TR, Hum DW. 3’-azido-3’-deoxythimidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7). Drug Metab Dispos 2000;28:497–502. PMID: 10772627 Barbier O Turgeon D Girard C Green MD Tephly TR Hum DW 3’-azido-3’-deoxythimidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7) Drug Metab Dispos 2000 28497 502 PMID: 10772627Search in Google Scholar

74Wang H, Yuan L, Zeng S. Characterizing the effect of UDP-glucuronosyltransferase (UGT) 2B7 and UGT1A9 genetic polymorphisms on enantioselective glucuronidation of flurbiprofen. Biochem Pharmacol 2011;82:1757–63. doi: 10.1016/j.bcp.2011.08.004 Wang H Yuan L Zeng S Characterizing the effect of UDP-glucuronosyltransferase (UGT) 2B7 and UGT1A9 genetic polymorphisms on enantioselective glucuronidation of flurbiprofen Biochem Pharmacol 2011 821757 63 10.1016/j.bcp.2011.08.00421856293Open DOISearch in Google Scholar

75Duguay Y, Báár C, Skorpen F, Guillemette C. A novel functional polymorphism in the uridine diphosphate-glucuronosyltransferase 2B7 promoter with significant impact on promoter activity. Clin Pharmacol Ther 2004;75:223–33. doi: 10.1016/j.clpt.2003.10.006 Duguay Y Báár C, Skorpen F Guillemette C A novel functional polymorphism in the uridine diphosphate-glucuronosyltransferase 2B7 promoter with significant impact on promoter activity Clin Pharmacol Ther 2004 75223 33 10.1016/j.clpt.2003.10.00615001974Open DOISearch in Google Scholar

76Thibaudeau J, Lépine J, Tojcic J, Duguay Y, Pelletier G, Plante M, Brisson J, Têtu B, Jacob S, Perusse L, Bélanger A, Guillemette C. Characterization of common UGT1A8, UGT1A9, and UGT2B7 variants with different capacities to inactivate mutagenic 4-hydroxylated metabolites of estradiol and estrone. Cancer Res 2006;66:125–33. doi: 10.1158/0008-5472.CAN-05-2857 Thibaudeau J Lépine J, Tojcic J Duguay Y Pelletier G Plante M Brisson J Têtu B, Jacob S Perusse L Bélanger A, Guillemette C Characterization of common UGT1A8, UGT1A9, and UGT2B7 variants with different capacities to inactivate mutagenic 4-hydroxylated metabolites of estradiol and estrone Cancer Res 2006 66125 33 10.1158/0008-5472.CAN-05-285716397224Open DOISearch in Google Scholar

77Urban TJ, Shen Y, Stolz A, Chalasani N, Fontana RJ, Rochon J, Ge D, Shianna KV, Daly AK, Lucena MI, Nelson MR, Molokhia M, Aithal GP, Floratos A, Pe’er I, Serrano J, Bonkovsky H, Davern TJ, Lee WM, Navarro VJ, Talwalkar JA, Goldstein DB, Watkins PB, on behalf of the Drug-Induced Liver Injury Network, DILIGEN, EUDRAGENE, the Spanish DILI Registry, and the International Serious Adverse Events Consortium. Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. Pharmacogenet Genomics 2012;22:784–95. doi: 10.1097/FPC.0b013e3283589a76 Urban TJ Shen Y Stolz A Chalasani N Fontana RJ Rochon J Ge D Shianna KV Daly AK Lucena MI Nelson MR Molokhia M Aithal GP Floratos A Pe’er I Serrano J Bonkovsky H Davern TJ Lee WM Navarro VJ Talwalkar JA Goldstein DB Watkins PB on behalf of the Drug-Induced Liver Injury Network DILIGEN, EUDRAGENE the Spanish DILI Registry and the International Serious Adverse Events Consortium Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs Pharmacogenet Genomics 2012 22784 95 10.1097/FPC.0b013e3283589a76363671622968431Open DOISearch in Google Scholar

78Lagas JS, van der Kruijssen CM, van de Wetering K, Beijnen JH, Schinkel AH. Transport of diclofenac by breast cancer resistance protein (ABCG2) and stimulation of multidrug resistance protein 2 (ABCC2)-mediated drug transport by diclofenac and benzbromarone. Drug Metab Dispos 2009;37:129–36. doi: 10.1124/dmd.108.02320. Lagas JS van der Kruijssen CM van de Wetering K Beijnen JH Schinkel AH Transport of diclofenac by breast cancer resistance protein (ABCG2) and stimulation of multidrug resistance protein 2 (ABCC2)-mediated drug transport by diclofenac and benzbromarone Drug Metab Dispos 2009 37129 36 10.1124/dmd.108.02320Open DOISearch in Google Scholar

79Daly AK. Are polymorphisms in genes relevant to drug disposition predictors of susceptibility to drug-induced liver injury? Pharm Res 2017;34:1564–9. doi: 10.1007/s11095-016-2091-1 Daly AK Are polymorphisms in genes relevant to drug disposition predictors of susceptibility to drug-induced liver injury? Pharm Res 2017 341564 9 10.1007/s11095-016-2091-1549865028028769Open DOISearch in Google Scholar

80Haenisch S, Zimmermann U, Dazert E, Wruck CJ, Dazert P, Siegmund W, Kroemer HK, Warzok RW, Cascorbi I. Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex. Pharmacogenomics J 2007;7:56–65. doi: 10.1038/sj.tpj.6500403 Haenisch S Zimmermann U Dazert E Wruck CJ Dazert P Siegmund W Kroemer HK Warzok RW Cascorbi I Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex Pharmacogenomics J 2007 756 65 10.1038/sj.tpj.650040316788565Open DOISearch in Google Scholar

81Saku K, Zhang B, Noda K. Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial. Circ J 2011;75:1493–505. doi: 10.1253/circj. cj-10-1281 Saku K Zhang B Noda K Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial Circ J 2011 751493 505 10.1253/circj.cj-10-128121498906Open DOISearch in Google Scholar

82Ooba N, Sato T, Wakana A, Orii T, Kitamura M, Kokan A, Kurata H, Shimodozono Y, Matsui K, Yoshida H, Yamaguchi T, Kageyama S, Kubota K. A prospective stratified case-cohort study on statins and multiple adverse events in Japan. PLoS One 2014;9(5):e96919. doi: 10.1371/journal. pone.0096919 Ooba N Sato T Wakana A Orii T Kitamura M Kokan A Kurata H Shimodozono Y Matsui K Yoshida H Yamaguchi T Kageyama S Kubota K A prospective stratified case-cohort study on statins and multiple adverse events in Japan PLoS One 2014 9 5 e96919 10.1371/journal.pone.0096919401457724810427Open DOISearch in Google Scholar

83Staud F, Ceckova M, Micuda S, Pavek P. Expression and function of p-glycoprotein in normal tissues: effect on pharmacokinetics. Methods Mol Biol 2010;596:199–222. doi: 10.1007/978-1-60761-416-6_10 Staud F Ceckova M Micuda S Pavek P Expression and function of p-glycoprotein in normal tissues: effect on pharmacokinetics Methods Mol Biol 2010 596199 222 10.1007/978-1-60761-416-6_1019949926Open DOISearch in Google Scholar

84Duman I. Role of pharmacogenetics on response to statins: a genotype-based approach to statin therapy outcome. J Cardiol Ther 2014;1:111–20. doi: 10.6051/j.issn.2309-6861.2014.01.35 Duman I Role of pharmacogenetics on response to statins: a genotype-based approach to statin therapy outcome J Cardiol Ther 2014 1111 20 10.6051/j.issn.2309-6861.2014.01.35Open DOISearch in Google Scholar

85Zubiaur P, Benedicto MD, Villapalos-García G, Navares-Gómez M, Mejía-Abril G, Román M, Martín-Vílchez S, Ochoa D, Abad-Santos F. SLCO 1B1 phenotype and CYP3A5 polymorphism significantly affect atorvastatin bioavailability. J Pers Med 2021;11:1–15. doi: 10.3390/jpm11030204 Zubiaur P Benedicto MD Villapalos-García G Navares-Gómez M Mejía-Abril G Román M Martín-Vílchez S Ochoa D Abad-Santos F SLCO 1B1 phenotype and CYP3A5 polymorphism significantly affect atorvastatin bioavailability J Pers Med 2021 111 15 10.3390/jpm11030204799965133805706Open DOISearch in Google Scholar

86Fukunaga K, Nakagawa H, Ishikawa T, Kubo M, Mushiroda T. ABCB1 polymorphism is associated with atorvastatin-induced liver injury in Japanese population. BMC Genet 2016;17:79. doi: 10.1186/s12863-016-0390-5 Fukunaga K Nakagawa H Ishikawa T Kubo M Mushiroda T ABCB1 polymorphism is associated with atorvastatin-induced liver injury in Japanese population BMC Genet 2016 1779 10.1186/s12863-016-0390-5490689927296832Open DOISearch in Google Scholar

87Gandelman K, Fung GL, Messig M, Laskey R. Systemic exposure to atorvastatin between Asian and Caucasian subjects: a combined analysis of 22 studies. Am J Ther 2012;19:164–73. doi: 10.1097/MJT.0b013e3181f28fb5 Gandelman K Fung GL Messig M Laskey R Systemic exposure to atorvastatin between Asian and Caucasian subjects: a combined analysis of 22 studies Am J Ther 2012 19164 73 10.1097/MJT.0b013e3181f28fb520975528Open DOISearch in Google Scholar

88Karaca RO, Kalkisim S, Altinbas A, Kilincalp S, Yuksel I, Goktas MT, Yasar U, Bozkurt A, Babaoglu MO. Effects of genetic polymorphisms of cytochrome P450 enzymes and MDR1 transporter on pantoprazole metabolism and Helicobacter pylori eradication. Basic Clin Pharmacol Toxicol 2017;120:199–206. doi: 10.1111/bcpt.12667 Karaca RO Kalkisim S Altinbas A Kilincalp S Yuksel I Goktas MT Yasar U Bozkurt A Babaoglu MO Effects of genetic polymorphisms of cytochrome P450 enzymes and MDR1 transporter on pantoprazole metabolism and Helicobacter pylori eradication Basic Clin Pharmacol Toxicol 2017 120199 206 10.1111/bcpt.1266727611887Open DOISearch in Google Scholar

89Safar Z, Kis E, Erdo F, Zolnerciks JK, Krajcsi P. ABCG2/ BCRP: variants, transporter interaction profile of substrates and inhibitors. Expert Opin Drug Metab Toxicol 2019;15:313–28. doi: 10.1080/17425255.2019.1591373 Safar Z Kis E Erdo F Zolnerciks JK Krajcsi P ABCG2/ BCRP: variants, transporter interaction profile of substrates and inhibitors Expert Opin Drug Metab Toxicol 2019 15313–28 10.1080/17425255.2019.159137330856014Open DOISearch in Google Scholar

90Hu M, To KKW, Mak VWL, Tomlinson B. The ABCG2 transporter and its relations with the pharmacokinetics, drug interaction and lipid-lowering effects of statins. Expert Opin Drug Metab Toxicol 2011; 7:49 – 62. doi: 10.1517/17425255.2011.538383 Hu M To KKW Mak VWL Tomlinson B The ABCG2 transporter and its relations with the pharmacokinetics, drug interaction and lipid-lowering effects of statins Expert Opin Drug Metab Toxicol 2011; 7:49 – 62 10.1517/17425255.2011.53838321091277Open DOISearch in Google Scholar

91Tsamandouras N, Guo Y, Wendling T, Hall S, Galetin A, Aarons L. Modelling of atorvastatin pharmacokinetics and the identification of the effect of a BCRP polymorphism in the Japanese population. Pharmacogenet Genomics 2017;27:27–38. doi: 10.1097/FPC.0000000000000252 Tsamandouras N Guo Y Wendling T Hall S Galetin A Aarons L Modelling of atorvastatin pharmacokinetics and the identification of the effect of a BCRP polymorphism in the Japanese population Pharmacogenet Genomics 2017 2727 38 10.1097/FPC.000000000000025227787353Open DOISearch in Google Scholar

92Mirosevic Skvrce N, Macolic Sarinic V, Simic I, Ganoci L, Muacevic Katanec D, Bozina N. ABCG2 gene polymorphisms as risk factors for atorvastatin adverse reactions: a case-control study. Pharmacogenomics 2015;16:803–15. doi: 10.2217/pgs.15.47 Mirosevic Skvrce N Macolic Sarinic V Simic I Ganoci L Muacevic Katanec D Bozina N ABCG2 gene polymorphisms as risk factors for atorvastatin adverse reactions: a case-control study Pharmacogenomics 2015 16803 15 10.2217/pgs.15.4726086347Open DOISearch in Google Scholar

93US Food and Drug Administration. Clinical Drug Interaction Studies - Study Design, Data Analysis, and Clinical Implications. Guidance for Industry [displayed 30 April 2021]. Available at https://www.fda.gov/drugs/drug-interactions-labeling/drug-interactions-relevant-regulatory-guidance-and-policy-documents US Food and Drug Administration. >Clinical Drug Interaction Studies - Study Design, Data Analysis, and Clinical Implications. Guidance for Industry [displayed 30 April 2021 Available at https://www.fda.gov/drugs/drug-interactions-labeling/drug-interactions-relevant-regulatory-guidance-and-policy-documentsSearch in Google Scholar

94European Medicines Agency. Guideline on the investigation of drug interactions CPMP/EWP/560/95/rev. 1 Corr. 2**. Committee for Human Medicinal Products (CHMP) [displayed 30 April 2021]. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/%0AWC500129606.pdf European Medicines Agency Guideline on the investigation of drug interactions CPMP/EWP/560/95/rev. 1 Corr. 2**. Committee for Human Medicinal Products (CHMP) [displayed 30 April 2021 Available at http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/%0AWC500129606.pdfSearch in Google Scholar

95Endres CJ, Hsiao P, Chung FS, Unadkat JD. The role of transporters in drug interactions. Eur J Pharm Sci 2006;27:501–17. doi: 10.1016/j.ejps.2005.11.002 Endres CJ Hsiao P Chung FS Unadkat JD The role of transporters in drug interactions Eur J Pharm Sci 2006 27501 17 10.1016/j.ejps.2005.11.00216364611Open DOISearch in Google Scholar

96Hermann M, Bogsrud MP, Molden E, Asberg A, Mohebi BU, Ose L, Retterstøl K. Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy. Clin Pharmacol Ther 2006;79:532–9. doi: 10.1016/j. clpt.2006.02.014 Hermann M Bogsrud MP Molden E Asberg A Mohebi BU Ose L Retterstøl K Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy Clin Pharmacol Ther 2006 79532 9 10.1016/j.clpt.2006.02.01416765141Open DOISearch in Google Scholar

97Stormo C, Bogsrud MP, Hermann M, Åsberg A, Piehler AP, Retterstøl K, Kringen MK. UGT1A1*28 is associated with decreased systemic exposure of atorvastatin lactone. Mol Diagn Ther 2013;17:233–7. doi: 10.1007/s40291-013-0031-x Stormo C Bogsrud MP Hermann M Åsberg A Piehler AP Retterstøl K Kringen MK UGT1A1*28 is associated with decreased systemic exposure of atorvastatin lactone Mol Diagn Ther 2013 17233 7 10.1007/s40291-013-0031-x23580084Open DOISearch in Google Scholar

98Sakaeda T, Kadoyama K, Okuno Y. Statin-associated muscular and renal adverse events: data mining of the public version of the FDA adverse event reporting system. PLoS One 2011;6(12):e28124. doi: 10.1371/journal.pone.0028124 Sakaeda T Kadoyama K Okuno Y Statin-associated muscular and renal adverse events: data mining of the public version of the FDA adverse event reporting system PLoS One 2011 6 12 e28124 10.1371/journal.pone.0028124324368322205938Open DOISearch in Google Scholar

99Chang C-H, Kusama M, Ono S, Sugiyama Y, Orii T, Akazawa M. Assessment of statin-associated muscle toxicity in Japan: a cohort study conducted using claims database and laboratory information. BMJ Open 2013;3(4):e002040. doi: 10.1136/bmjopen-2012-002040 Chang C-H Kusama M Ono S Sugiyama Y Orii T Akazawa M Assessment of statin-associated muscle toxicity in Japan: a cohort study conducted using claims database and laboratory information BMJ Open 2013 3 4 e002040 10.1136/bmjopen-2012-002040364142423585384Open DOISearch in Google Scholar

100Elsby R, Hilgendorf C, Fenner K. Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it’s not just about OATP1B1. Clin Pharmacol Ther 2012;92:584–98. doi: 10.1038/clpt.2012.163 Elsby R Hilgendorf C Fenner K Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it’s not just about OATP1B1 Clin Pharmacol Ther 2012 92584 98 10.1038/clpt.2012.16323047648Open DOISearch in Google Scholar

101National Center for Biotechnology Information. Reference SNP (rs) Report [displayed 30 April 2021]. Available at https://www.ncbi.nlm.nih.gov/snp/rs4149056#frequency_tab National Center for Biotechnology Information Reference SNP (rs) Report [displayed 30 April 2021 Available at https://www.ncbi.nlm.nih.gov/snp/rs4149056#frequency_tabSearch in Google Scholar

102Tarantino N, Santoro F, De Gennaro L, Correale M, Guastafierro F, Gaglione A, Di Biase M, Brunetti ND. Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy. Vasc Health Risk Manag 2017;13:29–41. doi: 10.2147/VHRM.S95044 Tarantino N Santoro F De Gennaro L Correale M Guastafierro F Gaglione A Di Biase M Brunetti ND Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy Vasc Health Risk Manag 2017 1329 41 10.2147/VHRM.S95044531732828243111Open DOISearch in Google Scholar

103Prueksaritanont T, Richards KM, Qiu Y, Strong-Basalyga K, Miller A, Li C, Eisenhandler R, Carlini EJ. Comparative effects of fibrates on drug metabolizing enzymes in human hepatocytes. Pharm Res 2005;22:71–8. doi: 10.1007/s11095-004-9011-5 Prueksaritanont T Richards KM Qiu Y Strong-Basalyga K Miller A Li C Eisenhandler R Carlini EJ Comparative effects of fibrates on drug metabolizing enzymes in human hepatocytes Pharm Res 2005 2271 8 10.1007/s11095-004-9011-515771232Open DOISearch in Google Scholar

104Davidson MH. Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions. Expert Opin Drug Saf 2006;5:145–56. doi: 10.1517/14740338.5.1.145 Davidson MH Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions Expert Opin Drug Saf 2006 5145 56 10.1517/14740338.5.1.14516370963Open DOISearch in Google Scholar

105Yamazaki M, Li B, Louie SW, Pudvah NT, Stocco R, Wong W, Abramovitz M, Demartis A, Laufer R, Hochman JH, Prueksaritanont T, Lin JH. Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport. Xenobiotica 2005; 35: 737 – 53 . doi: 10.1080/00498250500136676 Yamazaki M Li B Louie SW Pudvah NT Stocco R Wong W Abramovitz M Demartis A Laufer R Hochman JH Prueksaritanont T Lin JH Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport Xenobiotica 2005; 35: 737 – 53 10.1080/0049825050013667616316932Open DOISearch in Google Scholar

106Poruba M, Matuskova Z, Hüttl M, Malinska H, Oliyarnyk O, Markova I, Gurska S, Kazdova L, Vecera R. Fenofibrate decreases hepatic P-glycoprotein in a rat model of hereditary hypertriglyceridemia. Front Pharmacol 2019;10:56. doi: 10.3389/fphar.2019.00056 Poruba M Matuskova Z Hüttl M, Malinska H Oliyarnyk O Markova I Gurska S Kazdova L Vecera R Fenofibrate decreases hepatic P-glycoprotein in a rat model of hereditary hypertriglyceridemia Front Pharmacol 2019 1056 10.3389/fphar.2019.00056637346030787874Open DOISearch in Google Scholar

107Wen X, Wang J-S, Backman JT, Laitila J, Neuvonen PJ. Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively. Drug Metab Dispos 2002;30:631–5. doi: 10.1124/dmd.30.6.631 Wen X Wang J-S Backman JT Laitila J Neuvonen PJ Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively Drug Metab Dispos 2002 30631 5 10.1124/dmd.30.6.63112019187Open DOISearch in Google Scholar

108Turner RM, Fontana V, FitzGerald R, Morris AP, Pirmohamed M. Investigating the clinical factors and comedications associated with circulating levels of atorvastatin and its major metabolites in secondary prevention. Br J Clin Pharmacol 2020;86:62–74. doi: 10.1111/bcp.14133 Turner RM Fontana V FitzGerald R Morris AP Pirmohamed M Investigating the clinical factors and comedications associated with circulating levels of atorvastatin and its major metabolites in secondary prevention Br J Clin Pharmacol 2020 8662 74 10.1111/bcp.14133698351431656041Open DOISearch in Google Scholar

109Li XQ, Andersson TB, Ahlström M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 2004;32:821–7. doi: 10.1124/dmd.32.8.821 Li XQ Andersson TB Ahlström M Weidolf L Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities Drug Metab Dispos 2004 32821 7 10.1124/dmd.32.8.82115258107Open DOISearch in Google Scholar

110Pauli-Magnus C, Rekersbrink S, Klotz U, Fromm MF. Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol 2001;364:551–7. doi: 10.1007/s00210-001-0489-715 Pauli-Magnus C Rekersbrink S Klotz U Fromm MF Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein Naunyn Schmiedebergs Arch Pharmacol 2001 364551 7 10.1007/s00210-001-0489-715Open DOISearch in Google Scholar

111Luciani F, Spada M, De Milito A, Molinari A, Rivoltini L, Montinaro A, Marra M, Lugini L, Logozzi M, Lozupone F, Federici C, Iessi E, Parmiani G, Arancia G, Belardelli F, Fais S. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Cancer Inst 2004;96:1702–13. doi: 10.1093/jnci/djh305 Luciani F Spada M De Milito A Molinari A Rivoltini L Montinaro A Marra M Lugini L Logozzi M Lozupone F Federici C Iessi E Parmiani G Arancia G Belardelli F Fais S Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs J Natl Cancer Inst 2004 961702 13 10.1093/jnci/djh30515547183Open DOISearch in Google Scholar

112Balayssac D, Authier N, Cayre A, Coudore F. Does inhibition of P-glycoprotein lead to drug-drug interactions? Toxicol Lett 2005;156:319–29. doi: 10.1016/j.toxlet.2004.12.008 Balayssac D Authier N Cayre A Coudore F Does inhibition of P-glycoprotein lead to drug-drug interactions? Toxicol Lett 2005 156319 29 10.1016/j.toxlet.2004.12.00815763631Open DOISearch in Google Scholar

113Nakaharai K, Sakamoto Y, Yaita K, Yoshimura Y, Igarashi S, Tachikawa N. Drug-induced liver injury associated with high-dose ceftriaxone: a retrospective cohort study adjusted for the propensity score. Eur J Clin Pharmacol 2016;72:1003–11. doi: 10.1007/s00228-016-2064-7 Nakaharai K Sakamoto Y Yaita K Yoshimura Y Igarashi S Tachikawa N Drug-induced liver injury associated with high-dose ceftriaxone: a retrospective cohort study adjusted for the propensity score Eur J Clin Pharmacol 2016 721003–11 10.1007/s00228-016-2064-727126206Open DOISearch in Google Scholar

114Ebner T, Ishiguro N, Taub ME. The use of transporter probe drug cocktails for the assessment of transporter-based drug-drug interactions in a clinical setting-proposal of a four component transporter cocktail. J Pharm Sci 2015;104:3220–8. doi: 10.1002/jps.24489 Ebner T Ishiguro N Taub ME The use of transporter probe drug cocktails for the assessment of transporter-based drug-drug interactions in a clinical setting-proposal of a four component transporter cocktail J Pharm Sci 2015 1043220–8 10.1002/jps.2448925981193Open DOISearch in Google Scholar

115Hasegawa M, Kusuhara H, Adachi M, Schuetz JD, Takeuchi K, Sugiyama Y. Multidrug resistance-associated protein 4 is involved in the urinary excretion of hydrochlorothiazide and furosemide. J Am Soc Nephrol 2007;18:37–45. doi: 10.1681/ ASN.2005090966 Hasegawa M Kusuhara H Adachi M Schuetz JD Takeuchi K Sugiyama Y Multidrug resistance-associated protein 4 is involved in the urinary excretion of hydrochlorothiazide and furosemide J Am Soc Nephrol 2007 1837 45 10.1681/ASN.200509096617135398Open DOISearch in Google Scholar

116Klarica Domjanović I, Lovrić M, Trkulja V, Petelin-Gadže Ž, Ganoci L, Čajić I, Božina N. Interaction between ABCG2 421C>A polymorphism and valproate in their effects on steady-state disposition of lamotrigine in adults with epilepsy. Br J Clin Pharmacol 2018;84:2106–19. doi: 10.1111/bcp.13646 Klarica Domjanović I Lovrić M Trkulja V Petelin-Gadže Ž Ganoci L Čajić I Božina N Interaction between ABCG2 421C>A polymorphism and valproate in their effects on steady-state disposition of lamotrigine in adults with epilepsy Br J Clin Pharmacol 2018 842106 19 10.1111/bcp.13646608981529791014Open DOISearch in Google Scholar